EquitySector - HealthcareVery High Risk
Direct
NAV (15-Oct-25)
Returns (Since Inception)
Fund Size
₹6,227 Cr
Expense Ratio
1.04%
ISIN
INF109KC1GH2
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.66%
— (Cat Avg.)
3 Years
+28.92%
+22.68% (Cat Avg.)
5 Years
+21.39%
+17.53% (Cat Avg.)
Since Inception
+22.35%
— (Cat Avg.)
Equity | ₹6,074.12 Cr | 97.55% |
Others | ₹152.7 Cr | 2.45% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹721.19 Cr | 11.58% |
Dr Reddy's Laboratories Ltd | Equity | ₹566.95 Cr | 9.10% |
Divi's Laboratories Ltd | Equity | ₹544.91 Cr | 8.75% |
Aurobindo Pharma Ltd | Equity | ₹513.73 Cr | 8.25% |
Cipla Ltd | Equity | ₹430.94 Cr | 6.92% |
Lupin Ltd | Equity | ₹338.23 Cr | 5.43% |
Alkem Laboratories Ltd | Equity | ₹252.35 Cr | 4.05% |
Biocon Ltd | Equity | ₹193.7 Cr | 3.11% |
Gland Pharma Ltd | Equity | ₹184.82 Cr | 2.97% |
Mankind Pharma Ltd | Equity | ₹183.41 Cr | 2.95% |
Zydus Lifesciences Ltd | Equity | ₹172.94 Cr | 2.78% |
Treps | Cash - Repurchase Agreement | ₹160.51 Cr | 2.58% |
Syngene International Ltd | Equity | ₹137.41 Cr | 2.21% |
Medi Assist Healthcare Services Ltd | Equity | ₹112.88 Cr | 1.81% |
Alembic Pharmaceuticals Ltd | Equity | ₹106.15 Cr | 1.70% |
Cohance Lifesciences Ltd | Equity | ₹102.33 Cr | 1.64% |
Pfizer Ltd | Equity | ₹91.14 Cr | 1.46% |
Metropolis Healthcare Ltd | Equity | ₹89.21 Cr | 1.43% |
Thyrocare Technologies Ltd | Equity | ₹86.75 Cr | 1.39% |
Sagility Ltd | Equity | ₹81.29 Cr | 1.31% |
Anthem Biosciences Ltd | Equity | ₹80.13 Cr | 1.29% |
Windlas Biotech Ltd | Equity | ₹77.69 Cr | 1.25% |
Aarti Drugs Ltd | Equity | ₹73.99 Cr | 1.19% |
Glenmark Pharmaceuticals Ltd | Equity | ₹73.97 Cr | 1.19% |
Shilpa Medicare Ltd | Equity | ₹72.54 Cr | 1.17% |
Medplus Health Services Ltd | Equity | ₹70.98 Cr | 1.14% |
Blue Jet Healthcare Ltd | Equity | ₹70.69 Cr | 1.14% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹68.39 Cr | 1.10% |
Star Health and Allied Insurance Co Ltd | Equity | ₹67.88 Cr | 1.09% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹67.35 Cr | 1.08% |
Emcure Pharmaceuticals Ltd | Equity | ₹57.05 Cr | 0.92% |
FDC Ltd | Equity | ₹52.97 Cr | 0.85% |
Laxmi Dental Ltd | Equity | ₹52.28 Cr | 0.84% |
AstraZeneca Pharma India Ltd | Equity | ₹50.1 Cr | 0.80% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹49.88 Cr | 0.80% |
Procter & Gamble Health Ltd | Equity | ₹47.78 Cr | 0.77% |
Senores Pharmaceuticals Ltd | Equity | ₹44.1 Cr | 0.71% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹38.29 Cr | 0.61% |
Hikal Ltd | Equity | ₹27.6 Cr | 0.44% |
Net Current Assets | Cash | ₹-16.22 Cr | 0.26% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹15.05 Cr | 0.24% |
Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.13% |
Advanced Enzyme Technologies Ltd | Equity | ₹4.47 Cr | 0.07% |
Ipca Laboratories Ltd | Equity | ₹0.62 Cr | 0.01% |
Large Cap Stocks
47.51%
Mid Cap Stocks
16.61%
Small Cap Stocks
32.14%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹5,934.41 Cr | 95.30% |
Basic Materials | ₹71.83 Cr | 1.15% |
Financial Services | ₹67.88 Cr | 1.09% |
Standard Deviation
This fund
15.67%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
1.24
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GH2 | Expense Ratio 1.04% | Exit Load 1.00% | Fund Size ₹6,227 Cr | Age 7 years 3 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹10,52,087 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (15-Oct-25)
Returns (Since Inception)
Fund Size
₹6,227 Cr
Expense Ratio
1.04%
ISIN
INF109KC1GH2
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.66%
— (Cat Avg.)
3 Years
+28.92%
+22.68% (Cat Avg.)
5 Years
+21.39%
+17.53% (Cat Avg.)
Since Inception
+22.35%
— (Cat Avg.)
Equity | ₹6,074.12 Cr | 97.55% |
Others | ₹152.7 Cr | 2.45% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹721.19 Cr | 11.58% |
Dr Reddy's Laboratories Ltd | Equity | ₹566.95 Cr | 9.10% |
Divi's Laboratories Ltd | Equity | ₹544.91 Cr | 8.75% |
Aurobindo Pharma Ltd | Equity | ₹513.73 Cr | 8.25% |
Cipla Ltd | Equity | ₹430.94 Cr | 6.92% |
Lupin Ltd | Equity | ₹338.23 Cr | 5.43% |
Alkem Laboratories Ltd | Equity | ₹252.35 Cr | 4.05% |
Biocon Ltd | Equity | ₹193.7 Cr | 3.11% |
Gland Pharma Ltd | Equity | ₹184.82 Cr | 2.97% |
Mankind Pharma Ltd | Equity | ₹183.41 Cr | 2.95% |
Zydus Lifesciences Ltd | Equity | ₹172.94 Cr | 2.78% |
Treps | Cash - Repurchase Agreement | ₹160.51 Cr | 2.58% |
Syngene International Ltd | Equity | ₹137.41 Cr | 2.21% |
Medi Assist Healthcare Services Ltd | Equity | ₹112.88 Cr | 1.81% |
Alembic Pharmaceuticals Ltd | Equity | ₹106.15 Cr | 1.70% |
Cohance Lifesciences Ltd | Equity | ₹102.33 Cr | 1.64% |
Pfizer Ltd | Equity | ₹91.14 Cr | 1.46% |
Metropolis Healthcare Ltd | Equity | ₹89.21 Cr | 1.43% |
Thyrocare Technologies Ltd | Equity | ₹86.75 Cr | 1.39% |
Sagility Ltd | Equity | ₹81.29 Cr | 1.31% |
Anthem Biosciences Ltd | Equity | ₹80.13 Cr | 1.29% |
Windlas Biotech Ltd | Equity | ₹77.69 Cr | 1.25% |
Aarti Drugs Ltd | Equity | ₹73.99 Cr | 1.19% |
Glenmark Pharmaceuticals Ltd | Equity | ₹73.97 Cr | 1.19% |
Shilpa Medicare Ltd | Equity | ₹72.54 Cr | 1.17% |
Medplus Health Services Ltd | Equity | ₹70.98 Cr | 1.14% |
Blue Jet Healthcare Ltd | Equity | ₹70.69 Cr | 1.14% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹68.39 Cr | 1.10% |
Star Health and Allied Insurance Co Ltd | Equity | ₹67.88 Cr | 1.09% |
Fine Organic Industries Ltd Ordinary Shares | Equity | ₹67.35 Cr | 1.08% |
Emcure Pharmaceuticals Ltd | Equity | ₹57.05 Cr | 0.92% |
FDC Ltd | Equity | ₹52.97 Cr | 0.85% |
Laxmi Dental Ltd | Equity | ₹52.28 Cr | 0.84% |
AstraZeneca Pharma India Ltd | Equity | ₹50.1 Cr | 0.80% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹49.88 Cr | 0.80% |
Procter & Gamble Health Ltd | Equity | ₹47.78 Cr | 0.77% |
Senores Pharmaceuticals Ltd | Equity | ₹44.1 Cr | 0.71% |
Sun Pharma Advanced Research Co Ltd | Equity | ₹38.29 Cr | 0.61% |
Hikal Ltd | Equity | ₹27.6 Cr | 0.44% |
Net Current Assets | Cash | ₹-16.22 Cr | 0.26% |
Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹15.05 Cr | 0.24% |
Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.13% |
Advanced Enzyme Technologies Ltd | Equity | ₹4.47 Cr | 0.07% |
Ipca Laboratories Ltd | Equity | ₹0.62 Cr | 0.01% |
Large Cap Stocks
47.51%
Mid Cap Stocks
16.61%
Small Cap Stocks
32.14%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹5,934.41 Cr | 95.30% |
Basic Materials | ₹71.83 Cr | 1.15% |
Financial Services | ₹67.88 Cr | 1.09% |
Standard Deviation
This fund
15.67%
Cat. avg.
15.99%
Lower the better
Sharpe Ratio
This fund
1.24
Cat. avg.
0.92
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.64
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GH2 | Expense Ratio 1.04% | Exit Load 1.00% | Fund Size ₹6,227 Cr | Age 7 years 3 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹10,52,087 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments